Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $151.64, a high estimate of ...
1d
Assenagon Asset Management S.A. trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 62.2% in the ...
Analysts at HC Wainwright raised their FY2024 earnings estimates for Sarepta Therapeutics in a note issued to investors on ...
Mike Morin: We’re very proud to represent Sarepta Therapeutics, an innovative biotechnology company that focuses exclusively ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...
4d
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price ...
4d
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on SRPT stock, giving a Buy rating yesterday.Stay Ahead of the ...
'Mad Money' host Jim Cramer weighs in on stock including: Anavex Life Sciences, Sarepta Therapeutics, Viking Therapeutics, ...
Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that ...
Sarepta Therapeutics (NASDAQ:SRPT) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback